Risk factors for fingolimod-induced lymphopenia in multiple sclerosis.

Ryohei OhtaniMasahiro MoriTomohiko UchidaAkiyuki UzawaHiroki MasudaJia LiuSatoshi Kuwabara

Published in: Multiple sclerosis journal - experimental, translational and clinical (2018)

Low baseline ALC and treatment history with any interferon-beta were risk factors for fingolimod-induced lymphopenia, possibly predicted from ALC on day 2.

Keyphrases

multiple sclerosis
high glucose
diabetic rats
drug induced
dendritic cells
endothelial cells
replacement therapy